Literature DB >> 21264466

Antibacterial activity of Acinetobacter baumannii phage ϕAB2 endolysin (LysAB2) against both gram-positive and gram-negative bacteria.

Meng-Jiun Lai1, Nien-Tsung Lin, Anren Hu, Po-Chi Soo, Li-Kuang Chen, Long-Hui Chen, Kai-Chih Chang.   

Abstract

To investigate the nature and origin of the antibacterial activity of the lytic phage ϕAB2 toward Acinetobacter baumannii, we successfully isolated and characterized a novel phage lysozyme (endolysin) from ϕAB2 and named it LysAB2. To analyze antibacterial activity of LysAB2, the complete LysAB2 and two deletion derivatives were constructed, purified and characterized. Zymographic assays showed that only the intact LysAB2 could lyse the peptidoglycan of A. baumannii and the Staphylococcus aureus cell wall. Antibacterial analysis also showed that only the intact LysAB2 retained the complete bactericidal activity. When applied exogenously, LysAB2 exhibited a broad bacteriolytic activity against a number of Gram-negative and Gram-positive bacteria. Thermostability assays indicated that LysAB2 was stable at 20∼40 °C. Its optimal pH was 6.0, and it was active from pH 4 to 8. Scanning electron microscopy revealed that exposure to 500 μgml(-1) LysAB2 for up to 60 min caused a remarkable modification of the cell shape of the bacteria. Treating bacteria with LysAB2 clearly enhanced permeation of the bacterial cytoplasmic membrane. These results indicate that LysAB2 is an effective lysozyme against bacteria, and they suggest that it is a good candidate for a therapeutic/disinfectant agent to control nosocomial infections caused by multiple drug-resistant bacteria. © Springer-Verlag 2011

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21264466     DOI: 10.1007/s00253-011-3104-y

Source DB:  PubMed          Journal:  Appl Microbiol Biotechnol        ISSN: 0175-7598            Impact factor:   4.813


  63 in total

Review 1.  Recombinant Endolysins as Potential Therapeutics against Antibiotic-Resistant Staphylococcus aureus: Current Status of Research and Novel Delivery Strategies.

Authors:  Hamed Haddad Kashani; Mathias Schmelcher; Hamed Sabzalipoor; Elahe Seyed Hosseini; Rezvan Moniri
Journal:  Clin Microbiol Rev       Date:  2017-11-29       Impact factor: 26.132

Review 2.  Mechanisms of Bacterial Tolerance and Persistence in the Gastrointestinal and Respiratory Environments.

Authors:  R Trastoy; T Manso; L Fernández-García; L Blasco; A Ambroa; M L Pérez Del Molino; G Bou; R García-Contreras; T K Wood; M Tomás
Journal:  Clin Microbiol Rev       Date:  2018-08-01       Impact factor: 26.132

3.  Molecular aspects and comparative genomics of bacteriophage endolysins.

Authors:  Hugo Oliveira; Luís D R Melo; Sílvio B Santos; Franklin L Nóbrega; Eugénio C Ferreira; Nuno Cerca; Joana Azeredo; Leon D Kluskens
Journal:  J Virol       Date:  2013-02-13       Impact factor: 5.103

4.  Genomic and Biochemical Characterization of Acinetobacter Podophage Petty Reveals a Novel Lysis Mechanism and Tail-Associated Depolymerase Activity.

Authors:  A C Hernandez-Morales; L L Lessor; T L Wood; D Migl; E M Mijalis; J Cahill; W K Russell; R F Young; J J Gill
Journal:  J Virol       Date:  2018-02-26       Impact factor: 5.103

5.  Lysin LysMK34 of Acinetobacter baumannii Bacteriophage PMK34 Has a Turgor Pressure-Dependent Intrinsic Antibacterial Activity and Reverts Colistin Resistance.

Authors:  Karim Abdelkader; Diana Gutiérrez; Dennis Grimon; Patricia Ruas-Madiedo; Cédric Lood; Rob Lavigne; Amal Safaan; Ahmed S Khairalla; Yasser Gaber; Tarek Dishisha; Yves Briers
Journal:  Appl Environ Microbiol       Date:  2020-09-17       Impact factor: 4.792

6.  Novel Engineered Peptides of a Phage Lysin as Effective Antimicrobials against Multidrug-Resistant Acinetobacter baumannii.

Authors:  Mya Thandar; Rolf Lood; Benjamin Y Winer; Douglas R Deutsch; Chad W Euler; Vincent A Fischetti
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

7.  The antibacterial activity of E. coli bacteriophage lysin lysep3 is enhanced by fusing the Bacillus amyloliquefaciens bacteriophage endolysin binding domain D8 to the C-terminal region.

Authors:  Shuang Wang; Jingmin Gu; Meng Lv; Zhimin Guo; Guangmou Yan; Ling Yu; Chongtao Du; Xin Feng; Wenyu Han; Changjiang Sun; Liancheng Lei
Journal:  J Microbiol       Date:  2017-01-26       Impact factor: 3.422

Review 8.  Bacteriophage endolysins as novel antimicrobials.

Authors:  Mathias Schmelcher; David M Donovan; Martin J Loessner
Journal:  Future Microbiol       Date:  2012-10       Impact factor: 3.165

9.  Efficacy of Artilysin Art-175 against Resistant and Persistent Acinetobacter baumannii.

Authors:  Valerie Defraine; Joris Schuermans; Barbara Grymonprez; Sander K Govers; Abram Aertsen; Maarten Fauvart; Jan Michiels; Rob Lavigne; Yves Briers
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

Review 10.  Antimicrobial bacteriophage-derived proteins and therapeutic applications.

Authors:  Dwayne R Roach; David M Donovan
Journal:  Bacteriophage       Date:  2015-06-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.